Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Hydrogen water Clear all
Completed Phase 1Phase 2 Interventional Results available

Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL

NCT01752426
View directory record Official record
Conditions
Leukemia
Interventions
Heavy Water (2H2O), PCI-32765
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy

NCT01926444
View directory record Official record
Conditions
Pain, Cancer, Colonic Diseases
Interventions
GIC-1001
Drug
Lead sponsor
gicare Pharma Inc.
Industry
Eligibility
40 Years to 70 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
11
States / cities
Scottsdale, Arizona • Anaheim, California • Chula Vista, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 7, 2026, 10:35 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 7, 2026, 10:35 PM EDT
Recruiting Phase 1 Interventional

Effect of Insulin Lowering on Lipogenesis

NCT07403604
View directory record Official record
Conditions
Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions
Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST)
Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 7, 2026, 10:35 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex

NCT00956150
View directory record Official record
Conditions
Gulf War Syndrome
Interventions
Lactulose Breath Test, Rifaximin, Placebo
Procedure · Drug
Lead sponsor
Henry C. Lin, MD
Federal
Eligibility
21 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Results available

Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03687372
View directory record Official record
Conditions
Common Wart
Interventions
A-101, vehicle
Drug · Other
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
24
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 7, 2026, 10:35 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV

NCT02560805
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Microneurography, Combat virtual reality video clip, Handgrip Exercise, Cold Pressor Test (CPT), Sodium Nitroprusside (SNP), Phenylephrine, Losartan, Atenolol, Transcutaneous Vagal Nerve Stimulation (tVNS), Sham Transcutaneous Vagal Nerve Stimulation (tVNS)
Procedure · Behavioral · Drug + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 7, 2026, 10:35 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Immunology of Ebola Vaccine

NCT06100913
View directory record Official record
Conditions
Ebola Virus Disease
Interventions
Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP), Deuterium Labeled Water
Biological · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Decatur, Georgia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19

NCT05954286
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Upamostat, Placebo (PO)
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Baltimore, Maryland • Cleveland, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Aerosol in a Dental Clinic

NCT04659928
View directory record Official record
Conditions
Covid19
Interventions
High volume evacuation (HVE), Extraoral vacuum aspirator (EVA), Hydrogen Peroxide, Placebo
Device · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Not applicable Interventional

Hydrogen Water Treatment for Chronic Fatigue Syndrome

NCT05013606
View directory record Official record
Conditions
Chronic Fatigue Syndrome
Interventions
Hydrogen water
Dietary Supplement
Lead sponsor
Stony Brook University
Other
Eligibility
21 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Sep 7, 2026, 10:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adult Pilot Study for Reference Ranges and Optimal Cut-offs for the Sucrose Challenge Test and Sucrose Breath Test

NCT05045495
View directory record Official record
Conditions
Congenital Sucrase-Isomaltase Deficiency
Interventions
Sucrose Hydrogen Methane Breath Test
Diagnostic Test
Lead sponsor
QOL Medical, LLC
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 7, 2026, 10:35 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Neuro Biomarkers of Smoking Behavior

NCT03811951
View directory record Official record
Conditions
Smoking Cessation
Interventions
Novolin R
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
21 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent

NCT01681095
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Ischemia, Coronary Disease, Heart Diseases, Valvular Heart Disease
Interventions
Custodiol HTK, Cold Blood Cardioplegia
Drug
Lead sponsor
Marc Sakwa, MD
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia

NCT00956397
View directory record Official record
Conditions
Functional Dyspepsia, Small Intestinal Bacterial Overgrowth, Chronic Abdominal Discomfort
Interventions
Rifaximin, Lactulose Breath Test, Placebo
Drug · Procedure
Lead sponsor
Henry C. Lin, MD
Federal
Eligibility
21 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Sep 7, 2026, 10:35 PM EDT
Completed No phase listed Observational

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

NCT00900302
View directory record Official record
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Sep 7, 2026, 10:35 PM EDT
Recruiting Not applicable Interventional

Post-incision Antimicrobial Wash vs C. Acnes in Shoulder Arthroplasty

NCT06831422
View directory record Official record
Conditions
Shoulder Arthroplasty, Positive C. Acnes Culture
Interventions
Povidone-Iodine, Hydrogen Peroxide, Xperience Antimicrobial Wash, Bacterial Cultures, Shoulder Arthroplasty
Device · Diagnostic Test · Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 7, 2026, 10:35 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Hot Flashes and Neurovascular Function in Women

NCT05193968
View directory record Official record
Conditions
Hot Flashes, Menopause, Vasomotor System; Labile
Interventions
Sympathoexcitatory stressors, Sodium Nitroprusside, Acetylcholine, Terbutaline, Norepinephrine
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Phase 2Phase 3 Interventional Results available

ACTIV-2: A Study for Outpatients With COVID-19

NCT04518410
View directory record Official record
Conditions
Coronavirus, Covid19
Interventions
bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,044 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
207
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Sep 7, 2026, 10:35 PM EDT
Withdrawn No phase listed Observational

Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patients Who Receive Gliadel Wafers During Initial Surgery for Glioblastoma Multiforme. Response or Failure to Gliadel Wafers for Subjects With Glioblastoma Multiforme.

NCT00645385
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Interventions
MRS Spectroscopy
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Results available

A Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03691831
View directory record Official record
Conditions
Common Wart
Interventions
Active, Vehicle
Drug · Other
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
24
States / cities
Glendale, Arizona • Fort Smith, Arkansas • Encinitas, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Not applicable Interventional

Short-Term Endogenous Hydrogen Sulfide Upregulation

NCT03303534
View directory record Official record
Conditions
Carotid Stenosis, Caloric Restriction
Interventions
ScandiShake
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cold Induced Changes in White Adipose

NCT02596776
View directory record Official record
Conditions
Obese, Normal Body Weight, Prediabetes, Metabolic Syndrome
Interventions
Fat biopsy, Propranolol and fat biopsy, heavy water and fat biopsy
Procedure · Drug · Other
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 60 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

NCT02120352
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
CAB Oral Tablets, CAB LA, ABC/3TC Oral tablets, RPV Oral Tablets, HAART, RPV
Drug · Other
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Sep 7, 2026, 10:35 PM EDT